BioArctic AB (publ) Total Assets
BioArctic AB (publ) total assets. Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) holds total assets worth Skr2.82 Billion SEK (≈ $303.37 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BioArctic AB (publ) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of BioArctic AB (publ) (2015–2025)
Total assets of BioArctic AB (publ) from 2015 to 2025. This chart illustrates how BioArctic AB (publ)'s total assets have evolved over time, based on quarterly financial data. See BIOA-B stock price and chart for real-time trading data and today's change.
BioArctic AB (publ) - Asset Composition Analysis
BioArctic AB (publ) Total Assets Breakdown (December 2025)
BioArctic AB (publ) total assets breakdown as of December 2025. BioArctic AB (publ)'s total assets of Skr2.82 Billion consist of 96.6% current assets and 3.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr1.04 Billion | 40.4% |
| Accounts Receivable | Skr286.91 Million | 11.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr82.98 Million | 3.2% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how BioArctic AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BIOA-B net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioArctic AB (publ)'s current assets represent 96.6% of total assets in 2025, an increase from 90.3% in 2015.
- Cash Position: Cash and equivalents constituted 40.4% of total assets in 2025, down from 86.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 40.4% of total assets.
BioArctic AB (publ) Competitors by Total Assets
Key competitors of BioArctic AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
BioArctic AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.99 | 8.63 | 9.20 |
| Quick Ratio | 3.99 | 8.63 | 9.20 |
| Cash Ratio | 0.00 | 3.66 | 9.14 |
| Working Capital | Skr2.01 Billion | Skr1.98 Billion | Skr800.39 Million |
BioArctic AB (publ) - Advanced Valuation Insights
This section examines the relationship between BioArctic AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.38 |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | 131.7% |
| Total Assets | Skr2.58 Billion |
| Market Capitalization | $2.54 Billion USD |
Valuation Analysis
Near Book Valuation: The market values BioArctic AB (publ)'s assets close to their book value (0.99x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: BioArctic AB (publ)'s assets grew by 131.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioArctic AB (publ) (2015–2025)
The table below shows the annual total assets of BioArctic AB (publ) from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr2.58 Billion ≈ $277.14 Million |
+131.65% |
| 2024-12-31 | Skr1.11 Billion ≈ $119.63 Million |
-6.27% |
| 2023-12-31 | Skr1.19 Billion ≈ $127.64 Million |
+38.19% |
| 2022-12-31 | Skr858.31 Million ≈ $92.37 Million |
-4.39% |
| 2021-12-31 | Skr897.73 Million ≈ $96.61 Million |
-14.53% |
| 2020-12-31 | Skr1.05 Billion ≈ $113.03 Million |
-11.24% |
| 2019-12-31 | Skr1.18 Billion ≈ $127.35 Million |
-15.05% |
| 2018-12-31 | Skr1.39 Billion ≈ $149.91 Million |
+22.14% |
| 2017-12-31 | Skr1.14 Billion ≈ $122.73 Million |
+61.09% |
| 2016-12-31 | Skr707.98 Million ≈ $76.19 Million |
+439.98% |
| 2015-12-31 | Skr131.11 Million ≈ $14.11 Million |
-- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more